Leading the Way in Life Science Technologies

GEN Exclusives

More »

June 1, Vol. 36, No. 11

  • Feature Articles

    • Big Data Quickens the Life Sciences Enterprise
    • MaryAnn Labant
    • If you want to summarize the essentials of an activity or discipline, try an alliterative list, such as the “three R’s” or the “five D’s”  These examples, which pertain to education and dodgeball, respectively, come from popular culture Alliterative lists are found in ... more »
    • Systems Biology Digs Deep, Aims High
    • Richard A. Stein
    • Biotechnology, molecular biology, and genetic engineering share a firm foundation—a massive body of knowledge about individual cellular and subcellular components At the same time, these disciplines are limited in the same way They can rise only so high before ... more »
    • Transfection Methods in Gene Therapy
    • DeeAnn Visk
    • Immunotherapies against cancer, vaccines against new viruses (or old viruses in new places), and attempts to resolve pathogenic single-cell defects—all are looking to incorporate transfection technology This technology, which encompasses various means of introducing nucleic acids into cells, holds great promise, ... more »
    • One Algorithm. Many Cures. Zero Cancer?
    • Vicki Glaser
    • Pedro Domingos, PhD, professor of computer science and engineering at the University of Washington, believes that cancer can be eliminated if we get serious about machine learning, an approach to artificial intelligence (AI) that gives computers the ability to “think” ... more »
  • Tutorials

    • Translating from Molecules to Medicine
    • Don Rule
      Houda Hachad
    • With $215 million in funding, the federal government’s Precision Medicine Initiative ® is expected to generate the scientific evidence needed to move personalized medicine into clinical practice by providing clinicians with the knowledge and tools to determine more precise medical ... more »
    • Engineering Biotherapeutic Quality
    • Jamie Freeman
    • The first recombinant protein licensed for use by the US FDA was human insulin in 1982 This was closely followed by tissue plasminogen activator (tPA), the first complex glycosylated protein generated in mammalian cells to be licensed for therapeutic use ... more »